Agency / Source: Genentech, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration - Genentech announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab - Gene.com
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration

 

PRZOOM - /newswire/ - South San Francisco, CA, United States, 2017/09/08 - Genentech announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab - Gene.com. SIX: RO, ROG; OTCQX: RHHB

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment;
• Safety profile was in line with previous lampalizumab trials and other intravitreal therapies;
• Results from the second Phase III study, Chroma, are expected in November 2017.

Genentech, a member of the Roche Group, today announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). Lampalizumab did not reduce mean change in GA lesion area compared to sham treatment at one year (48 weeks). Given the lack of efficacy, further dosing in patients will be interrupted until the results from the second Phase III study are evaluated.

“Geographic atrophy is a progressive and irreversible disease that impairs vision, and there are currently no available treatments,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “While this result is disappointing, we will continue to evaluate results from Spectri to get a clearer understanding of the data as we await the results of our second Phase III study, Chroma, anticipated in November.”

About the Spectri and Chroma Studies
The Phase III trials, called Spectri (NCT02247531) and Chroma (NCT02247479) are identically-designed, double-masked, randomized, global studies evaluating the efficacy and safety of a 10 mg dose of lampalizumab administered every four or six weeks by intravitreal injection, versus sham injections in people with geographic atrophy (GA) due to age-related macular degeneration (AMD). Together, the studies enrolled more than 1,800 participants in more than 275 sites in over 20 countries.

The primary objective of the studies is to demonstrate a difference in mean change in GA lesion area in patients treated with lampalizumab compared to sham. This efficacy endpoint, evaluated at one year (week 48), is measured by fundus autofluorescence (FAF), an imaging technique used to provide information about the size and type of GA lesions in the macula. Secondary objectives of the studies, evaluated at two years (96 weeks), focus on assessing the impact of lampalizumab treatment on patients’ visual function.

About Lampalizumab
Lampalizumab is being investigated to determine its efficacy in reducing the progression of geographic atrophy (GA) due to age-related macular degeneration (AMD). Lampalizumab is an antigen-binding fragment (Fab) of a humanized, monoclonal antibody directed against complement factor D (CFD). CFD is a rate-limiting enzyme involved in the activation and amplification of the alternative complement pathway (ACP), a component of the immune system. Dysfunction of the alternative complement pathway has been linked to the pathogenesis of AMD through numerous genetic studies.

About Geographic Atrophy
Geographic atrophy (GA) is a progressive and irreversible form of age-related macular degeneration (AMD), affecting more than five million people worldwide. Visual impairment associated with GA tends to affect both eyes in many individuals. People with GA report visual problems with activities of daily living including reading, driving, recognizing faces, and activities in dim or low light. GA represents a significant unmet medical need, as there are no approved therapies for this condition.

About Genentech in Ophthalmology
Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including GA, neovascular AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and other retinal diseases.

Genentech medicines are indicated to treat several ophthalmic diseases and conditions including wet AMD, diabetic macular edema, diabetic retinopathy, macular edema secondary to retinal vein occlusion, myopic choroidal neovascularization and giant cell arteritis, a form of vasculitis that can lead to blindness.

About Genentech
Founded more than 40 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Genentech, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Genentech | Lampalizumab
Contact: Press Office - Gene.com 
650-467-6800 press[.]gene.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genentech, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Genentech, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®
DSM and Industry Partners Launch Coalition to Close the Loop on Dyneema® - The World’s Strongest Fiber™
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with its Differentiated Molecular Laboratory Information Management System
DSM Launches Three Times Faster-acting Form of Vitamin D Supplement in Australia to Support Immune Health
Ipsen Announces New Data from the Phase II CLARINET FORTE Study

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  Venus Promotions

Visit  JobsWare.com







 
  ©2021 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today